Beaver Addresses FDA’s Planned New Guidance for Drug Developers
December 29, 2017
BNA Health Care Blog
Partner Nathan Beaver was quoted in a BNA Health Care Blog article, ”FDA to Provide Earlier, Better Advice to Drug Developers,” about the FDA’s efforts to enhance its communications with drug suppliers as a way of lowering the cost of drug development.
Beaver said the FDA’s planned guidance doubles down on its commitment to partner with companies early and often in the drug development process. “Guidance on best practices and procedures for collaborating during drug development should be welcomed by industry,” he said, adding that FDA Commissioner Scott Gottlieb’s engagement on the issue is encouraging and “demonstrates his continued commitment to working with industry to increase the efficiency of the process.”
Beaver said the FDA’s planned guidance doubles down on its commitment to partner with companies early and often in the drug development process. “Guidance on best practices and procedures for collaborating during drug development should be welcomed by industry,” he said, adding that FDA Commissioner Scott Gottlieb’s engagement on the issue is encouraging and “demonstrates his continued commitment to working with industry to increase the efficiency of the process.”
People
Related News
August 8, 2025
In the News
Gregory Husisian and David Simon Uncover the High Stakes of Tariff Evasion
Foley & Lardner LLP partners Gregory Husisian and David Simon are featured for their insights on how the U.S. government is cracking down on tariff evaders in the Newsweek article, "America Is Making Billions From Catching 'Tariff Cheaters.'"
August 7, 2025
In the News
Kyle Faget Weighs in on Trump Pharma Tariffs
Foley & Lardner LLP partner Kyle Faget assessed the Trump administration's implementation of import tariffs on the pharmaceutical industry in the Pharma Life Sciences article, "Trump's pharma import tariffs threaten drug pricing, generics."
August 5, 2025
In the News
Aaron Maguregui on Health Data Sharing Plan – 'I would expect the FTC to be heavily involved'
Foley & Lardner LLP partner Aaron Maguregui addressed a new health care data sharing initiative announced by the federal government in the Bloomberg Law article, "Digital Data-Sharing Plan Tests Limits of Health Privacy Rules."